Remibrutinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg
Reference Brands: Generic formulations marketed under different names
Category:
Immune Disorder
Remibrutinib is available in Tablets
and strengths such as 25 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Remibrutinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Remibrutinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Remibrutinib is an oral, highly selective Bruton’s tyrosine kinase (BTK) inhibitor developed for the treatment of immune-mediated and inflammatory disorders. It is designed to target BTK, a key signaling enzyme involved in B-cell activation, antibody production, and downstream inflammatory pathways that contribute to autoimmune and allergic diseases.
By covalently and selectively inhibiting BTK, remibrutinib helps suppress abnormal immune responses while minimizing off-target effects commonly associated with earlier BTK inhibitors. This targeted mechanism supports effective control of inflammation and immune dysregulation without broad immunosuppression. Remibrutinib has shown promising clinical efficacy in reducing disease activity and symptom severity across multiple immune-driven conditions.
The drug is being developed by Novartis and has been evaluated extensively in clinical trials, particularly for chronic spontaneous urticaria and other inflammatory disorders where current treatment options may be limited or insufficient. Its oral administration offers added convenience for long-term disease management.
Through its precision-based approach and favorable safety profile observed in clinical studies, remibrutinib represents an important advancement in the next generation of targeted therapies for immune and inflammatory diseases, addressing unmet medical needs and improving patient quality of life.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing